WO1998034583A3 - Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones - Google Patents

Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones Download PDF

Info

Publication number
WO1998034583A3
WO1998034583A3 PCT/US1998/002176 US9802176W WO9834583A3 WO 1998034583 A3 WO1998034583 A3 WO 1998034583A3 US 9802176 W US9802176 W US 9802176W WO 9834583 A3 WO9834583 A3 WO 9834583A3
Authority
WO
WIPO (PCT)
Prior art keywords
permanently charged
agonist
steroid hormones
angiogenic activity
enhanced anti
Prior art date
Application number
PCT/US1998/002176
Other languages
French (fr)
Other versions
WO1998034583A2 (en
Inventor
Anat Biegon
Marcus E Brewster
Original Assignee
Pharmos Corp
Anat Biegon
Marcus E Brewster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12018497A external-priority patent/IL120184A/en
Priority claimed from US08/833,074 external-priority patent/US6083990A/en
Application filed by Pharmos Corp, Anat Biegon, Marcus E Brewster filed Critical Pharmos Corp
Priority to JP53487698A priority Critical patent/JP2001511182A/en
Priority to CA002280181A priority patent/CA2280181A1/en
Priority to AU60562/98A priority patent/AU746007B2/en
Priority to EP98903921A priority patent/EP0981337A4/en
Publication of WO1998034583A2 publication Critical patent/WO1998034583A2/en
Publication of WO1998034583A3 publication Critical patent/WO1998034583A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention discloses the use of permanently charged steroid agonists or antagonists as potent anti-angiogenic compositions comprising as an active ingredient a compound of general formulae (I), (II) or (III), wherein DRUG is any steroid agonist or antagonist, a mixed agonist-antagonist, or a partial agonist and the substituents are as defined in the specification. The effects of estradiol, tamoxifen, TMI or a placebo on the growth or MCF-7 tumors implanted in the vnetral fat pad of nude mice (see the figure). The left panel gives data for tamoxifen, TMI and the placebo, while the right panel adds the group treated with estradiol.
PCT/US1998/002176 1997-02-09 1998-02-04 Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones WO1998034583A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP53487698A JP2001511182A (en) 1997-02-09 1998-02-04 Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
CA002280181A CA2280181A1 (en) 1997-02-09 1998-02-04 Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
AU60562/98A AU746007B2 (en) 1997-02-09 1998-02-04 Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
EP98903921A EP0981337A4 (en) 1997-02-09 1998-02-04 Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL120184 1997-02-09
IL12018497A IL120184A (en) 1997-02-09 1997-02-09 Pharmaceutical compositions comprising permanently charged derivatives of steroid agonists or antagonists for preventing angiogenesis
US08/833,074 US6083990A (en) 1997-04-02 1997-04-02 Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
US08/833,074 1997-04-02

Publications (2)

Publication Number Publication Date
WO1998034583A2 WO1998034583A2 (en) 1998-08-13
WO1998034583A3 true WO1998034583A3 (en) 1998-11-05

Family

ID=26323367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/002176 WO1998034583A2 (en) 1997-02-09 1998-02-04 Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones

Country Status (5)

Country Link
EP (1) EP0981337A4 (en)
JP (1) JP2001511182A (en)
AU (1) AU746007B2 (en)
CA (1) CA2280181A1 (en)
WO (1) WO1998034583A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046792B1 (en) * 2016-01-19 2018-02-02 Les Laboratoires Servier NOVEL AMMONIUM DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA3032153A1 (en) * 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026720A1 (en) * 1994-04-04 1995-10-12 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914561A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethylene
US2971001A (en) * 1959-10-21 1961-02-07 Wm S Merrell Co Quaternary salts of triphenylethanols, -ethylenes, and -ethanes
BE637389A (en) * 1962-09-13
ES2128441T3 (en) * 1992-10-27 1999-05-16 Nippon Kayaku Kk USE OF TOREMIFENO TO TREAT SLE.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026720A1 (en) * 1994-04-04 1995-10-12 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0981337A4 *

Also Published As

Publication number Publication date
WO1998034583A2 (en) 1998-08-13
EP0981337A4 (en) 2003-03-12
EP0981337A2 (en) 2000-03-01
JP2001511182A (en) 2001-08-07
AU6056298A (en) 1998-08-26
CA2280181A1 (en) 1998-08-13
AU746007B2 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
HK1036969A1 (en) Compounds and compositions for delivering active agents
IL116643A (en) Tetrahydronaphthalene derivatives as estrogen agonists/antagonists and pharmaceutical compositions comprising them
AU2274201A (en) Compounds and compositions for delivering active agents
EP0993831A3 (en) Compounds and compositions for delivering active agents
AU6750996A (en) Oral fast-dissolving compositions for dopamine agonists
CA2338358A1 (en) Compounds and compositions for delivering active agents
AU5699399A (en) Pyridyl-bridgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors
EP0663401A4 (en) Morphinan derivative and medicinal use.
HUP9900582A3 (en) Halogen pyrimidine derivatives, intermediates, preparation and use thereof, pesticide compositions containing these compounds as active ingredients
DE60036807D1 (en) PROCESS FOR PREPARING A PHARMACEUTICAL CHEWING GUM
MXPA03000548A (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation.
EP1219631A4 (en) Antiandrogen agents
NZ326608A (en) Adenosine and xanthine derivative as a1 adenosine receptor agonists and antagonists
BG105136A (en) 4,5,6 and 7-indole and indoline derivatives, their preparation and use
HUP9901596A3 (en) Pyrazole derivatives, intermediates, preparation and use thereof, herbicide compositions containing these compounds as active ingredients
ES2189252T3 (en) ANALGESIC COMPOSITIONS THAT INCLUDE AN ANTAGONIST OF THE COLECISTOQUININE AND AN OPIOID.
WO2000073269A3 (en) Nicotine receptor ligands
WO1998034583A3 (en) Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
DE69727385D1 (en) BENZOPHENANTHRIDINE ALKALOID-CONTAINING PESTICIDES
HUT77000A (en) Substituted pyrazine derivatives, preparation and use thereof, and herbicide compositions containing these compounds as active ingredients
HUP9901104A3 (en) Pyrazole-4-yl-hetaroyl derivatives, preparation and use thereof, herbicide compositions containing these compounds as active ingredients
DE69526738T2 (en) Endothelin receptor Antagonist
HUP0104338A2 (en) Pharmaceutical compositions containing an estrogen agonist/antagonist as active ingredient for improving vascular health
EP0930314A4 (en) p-TOLUENESULFONATE HYDRATE OF THIAZOLINE COMPOUND
AU6122299A (en) Methyl acetate derivatives and pesticide compositions containing the same as theactive ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH GW HU ID IL IS JP KG KP KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH GW HU ID IL IS JP KG KP KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2280181

Country of ref document: CA

Ref country code: CA

Ref document number: 2280181

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1998 534876

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 60562/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998903921

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998903921

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 60562/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998903921

Country of ref document: EP